AKR inhibitors have been developed to target AKR1B1 for the treatment of complications that accompany T2DM and could be delivered by eye drops to treat diabetic cataracts, though further work is necessary to determine optimal delivery routes. This evidence concerns the gene AKR1B1 and type 2 diabetes mellitus.